Innovent's IBI306 Meets its Primary Endpoint in P-III CREDIT-2 Study for Heterozygous Familial Hypercholesterolemia
Shots:
- The P-III CREDIT-2 study evaluates the efficacy and safety of IBI306 vs PBO in 148 Chinese patients with HeFH- prior treated with statins and ezetimibe. The study provides high-quality clinical evidence for patients with the same indication
- The study met its 1EPs i.e.- reduction in the LDL-C levels @12wks. of continuous treatment & demonstrated a safety profile similar to the reported safety profiles of other marketed PCSK-9 inhibitors
- IBI306 is an lgG2 mAb that binds to PCSK-9. Additionally- P-I & IIa study for IBI306 demonstrated good efficacy with a favorable safety profile to treat patients with hypercholesterolemia
Ref: PR Newswire | Image: Innovent
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com